Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives

a technology of phenylbenzothiazole and pyridine, which is applied in the field of treatment of meningiomas, can solve the problems of severe mortality and even death, and achieve the effects of less success, side effects, and higher complications

Inactive Publication Date: 2015-06-11
MAYO FOUND FOR MEDICAL EDUCATION & RES
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new treatment for meningiomas, a type of brain tumor. There are currently no drugs that can treat meningiomas, and surgery and radiation are the main treatments options. However, not all tumors can be treated using these methods, and they can have side effects. The invention provides a new drug therapy that can be added to surgery and radiation, or used alone. This new therapy has shown promising results in treating meningiomas and can provide a better option for patients who have limited treatment options.

Problems solved by technology

Meningiomas are mostly benign, but can cause severe mortality and even death mostly due to mass effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
  • Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
  • Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0100]An Alzheimer's imaging database of two hundred forty-one patients was reviewed. Some of the patients had a history of cognitive impairment that might be due to early Alzheimer's disease and some were normal controls. All patients had been imaged by at least one MRI, as well as by FDG-PET / CT and PET / CT using the compound of formula (V). MRI reports of all patients were reviewed for possible meningiomas and other tumors. Seven patients were found to have the diagnosis of presumed meningioma based on MRI and sometimes also on CT. The diagnostic confidence of the radiologists interpreting the studies varied slightly, depending on factors such as tumor location and previous imaging. Of these seven tumors, six showed intense uptake of the compound of formula (V) on PET / CT. One showed some uptake, but was difficult to evaluate presumably because of its small size (˜4 mm. thick). Tumors smaller than 7 millimeters are generally considered too small to be evaluated by PET or PET / CT. Thi...

example 2

[0103]In Example 1, we identified six patients with meningiomas >5 millimeters in size that showed positive uptake of the compound of formula (V) on PET / CT. We identified three more patients with four presumed meningiomas. All three patients were imaged by PET-CT using the compound of formula (V), FDG PET-CT and MRI within as part of the ongoing amyloid imaging study. In one patient, there are two meningiomas. One is in the orbit, and is therefore extracranial. This orbital meningioma was previously resected and pathologically shown to be a meningioma in 1969, and pathology was confirmed later at our institution. It has now regrown within the orbit. The other meningioma is along the falx. Both show avid uptake of the compound of formula (V). There were two other patients with a single meningioma with uptake of the compound of formula (V). Therefore, there are a total of ten presumed meningiomas that show uptake of the compound of formula (V) on PET / CT.

example 3

[0104]In Examples 1 and 2, we identified ten patients with meningiomas >5 millimeters in size that showed positive uptake of the compound of formula (V) on PET / CT. We identified three more examples of presumed meningiomas that show activity using the compound of formula (V) on PET-CT, for a total of thirteen. All of these formula (V) avid meningiomas are >5 millimeters in size. We also identified three more presumed meningiomas that showed some positive uptake of formula (V), but were non-diagnostic due to common limitations of PET / CT imaging. One of these non-diagnostic presumed meningiomas was too small to evaluate by PET or PET / CT. One of these non-diagnostic presumed meningiomas was necrotic / cystic centrally with a 4 millimeter rim of tumor, and is therefore effectively also too small to evaluate by PET or PET / CT. The other of these non-diagnostic presumed meningiomas was only seen in the last 2 slices of PET data, an area considered to be uninterpretable. In addition, this pati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
body weightaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

A method and composition for treating a meningioma in a subject are disclosed. The method includes the step of administering to the subject a therapeutically effective amount of a composition including a cytotoxic agent associated with a phenylbenzothiazole derivative or a stilbene derivative or a biphenylalkyne derivative that accumulates within meningiomas. In one version of the method, the phenylbenzothiazole derivative is a compound of formula (V).

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application claims priority from U.S. Patent Application No. 61 / 665,000 filed Jun. 27, 2012.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH[0002]Not Applicable.BACKGROUND OF THE INVENTION[0003]1. Field of the Invention[0004]The invention relates to the treatment of meningiomas using a composition including a cytotoxic agent and a compound selected from phenylbenzothiazole derivatives, stilbene derivatives, biphenylalkyne derivatives, and imidazo[1,2-a]pyridine derivatives.[0005]2. Description of the Related Art[0006]Meningiomas are the second most common tumor inside the skull with an incidence of approximately six per 100,000, and meningiomas account for 13-26 percent of all primary intracranial tumors. Approximately 90% of meningiomas are benign, with the rest being more aggressive, or even malignant. The benign classifications include meningothelial meningioma, fibrous / fibroblastic meningioma, transitional (mixed) meningioma, ps...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K51/04A61K49/00A61K49/10
CPCA61K51/0453A61K49/00A61K49/10A61K31/428A61K45/06
Inventor JOHNSON, GEOFFREY B.LOWE, VAL J.NATHAN, MARK A.PARISI, JOSEPH E.
Owner MAYO FOUND FOR MEDICAL EDUCATION & RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com